Restless Leg Syndrome Associated with Vyvanse

Diagnostic Criteria

The American Geriatrics Society recommends assessing four criteria to confirm if Vyvanse is causing restless leg syndrome, including an urge to move the legs accompanied by uncomfortable sensations, symptoms beginning or worsening during rest, symptoms relieved by movement, and symptoms worsening in the evening or night 1

The American Academy of Sleep Medicine recommends against using dopamine agonists as first-line treatment for restless leg syndrome due to high risk of augmentation with long-term use, and instead suggests gabapentin, gabapentin enacarbil, or pregabalin as first-line therapy (strong recommendation, moderate certainty of evidence) 3
The management of restless leg syndrome associated with Vyvanse involves assessing and correcting iron status, evaluating medication necessity, and initiating first-line RLS treatment with gabapentinoids, with a recommended starting dose of gabapentin 300mg at bedtime, titrated up to 1800-2400mg/day divided into multiple doses as needed 2

The American Academy of Sleep Medicine recommends against using dopamine agonists as first-line treatment for restless leg syndrome due to high risk of augmentation with long-term use, which can cause earlier symptom onset, increased intensity, and spread to other body parts 3
The use of clonazepam as monotherapy is not recommended due to insufficient evidence of efficacy and potential side effects, including sedation and hepatotoxicity 2

Regular monitoring of ferritin levels every 6-12 months is recommended, even after symptom resolution, as brain iron deficiency may persist despite normal serum parameters 2